Ursodeoxycholic acid (UDCA) has one of the most favorable safety profiles among hepatoprotective agents. With over three decades of post-market surveillance, more than 15,000 patients studied in controlled clinical trials, and millions of patient-years of exposure, the safety data supporting UDCA is robust. This article aggregates safety information from clinical trial data, pharmacovigilance databases, and regulatory labeling for pharmaceutical buyers evaluating UDCA for formulation or procurement.
UDCA is classified as generally well-tolerated across all studied populations. In the pivotal Lindor et al. (1994) trial of UDCA for primary biliary cholangitis (PBC), adverse events occurred at similar rates in the UDCA and placebo arms, with no statistically significant difference in discontinuation rates. The drug's mechanism — replacing toxic hydrophobic bile acids from the enterohepatic circulation — is itself cytoprotective, which contributes to its benign safety profile. A 2017 Cochrane systematic review of 16 randomized clinical trials involving 1,447 participants with PBC confirmed no significant increase in serious adverse events with UDCA compared to placebo or no intervention (RR 1.04; 95% CI 0.79 to 1.37).
Diarrhea is the most frequently reported adverse event associated with UDCA, occurring in approximately 2-9% of patients depending on dose and study population. The mechanism is osmotic: unabsorbed bile acids in the colon stimulate chloride secretion and increase colonic motility. This effect is dose-dependent — higher per-kilogram doses (above 20 mg/kg/day) correlate with increased incidence — and typically mild to moderate in severity. In most cases, diarrhea resolves with dose reduction or resolves spontaneously within the first two weeks of treatment as the gastrointestinal tract adapts.
For pharmaceutical formulators, this side effect profile informs release kinetics: immediate-release UDCA tablets deliver a bolus of bile acid to the small intestine, while modified-release formulations (studied but less common in commercial products) can attenuate gastrointestinal effects by distributing UDCA delivery along a longer intestinal segment.
Pruritus, urticaria, and rash have been reported rarely (less than 1% incidence). Notably, UDCA is actually used to treat pruritus associated with cholestasis — when pruritus occurs during UDCA therapy, it is typically attributable to the underlying liver disease rather than the drug. Back pain, headache, dizziness, and fatigue appear in post-marketing surveillance reports but at rates indistinguishable from background population incidence.
The following conditions are listed as contraindications in UDCA prescribing information across major regulatory jurisdictions (FDA, EMA, PMDA):
| Contraindication | Rationale | Clinical Significance |
|---|---|---|
| Calcified gallstones | UDCA cannot dissolve radiopaque stones; these appear opaque on X-ray or CT | Screen all gallstone patients by imaging before initiating UDCA |
| Non-functioning gallbladder | UDCA requires gallbladder contraction to deliver dissolved bile acids to stones | Confirm gallbladder function via oral cholecystogram or HIDA scan |
| Acute cholecystitis / biliary colic | UDCA is not effective for acute biliary tract inflammation or obstruction | UDCA is indicated for chronic management, not acute episodes |
| Complete biliary obstruction | UDCA cannot reach its site of action if bile flow is mechanically blocked | Resolve obstruction before UDCA therapy |
| Hypersensitivity to UDCA or excipients | Standard contraindication for any drug | Rare; documented hypersensitivity to bile acids is extremely uncommon |
Cholestyramine, colestipol, and colesevelam bind UDCA in the intestinal lumen, preventing absorption and reducing therapeutic efficacy. This is the most clinically relevant UDCA drug interaction. The FDA prescribing information recommends separating UDCA and bile acid sequestrant administration by at least 2 hours (preferably 4-6 hours). In practice, patients taking cholestyramine in the morning should take UDCA in the evening, or vice versa. Pharmacokinetic studies demonstrate that co-administration can reduce UDCA bioavailability by 60-80%.
Aluminum hydroxide and aluminum-containing antacid formulations can bind UDCA in the gastrointestinal tract through ionic interactions between the negatively charged bile acid carboxyl group and positively charged aluminum ions. The clinical significance is moderate — separating doses by 2 hours mitigates the interaction. Calcium carbonate and magnesium-based antacids do not exhibit clinically significant binding with UDCA. For patients requiring antacid therapy, an H2 receptor antagonist or proton pump inhibitor may be preferred over aluminum antacids to avoid this interaction entirely.
UDCA is classified as Pregnancy Category B by the FDA under the legacy classification system (animal reproduction studies have failed to demonstrate a fetal risk, but no adequate and well-controlled studies exist in pregnant women). Under the current PLLR labeling format, the prescribing information notes that available data from published case reports, case series, and observational studies over several decades have not identified a UDCA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
UDCA is used off-label for intrahepatic cholestasis of pregnancy (ICP), a condition affecting approximately 0.5-1.5% of pregnancies in North America and up to 5% in certain South American populations. Multiple randomized trials, including the PITCHES trial (Chappell et al., 2019, The Lancet), have demonstrated safety and efficacy for this indication, with no increase in adverse fetal outcomes. This is the single application of UDCA with the largest body of pregnancy-specific safety evidence.
UDCA is used in pediatric hepatology at weight-adjusted doses for conditions including biliary atresia (post-Kasai procedure), progressive familial intrahepatic cholestasis (PFIC), and cystic fibrosis-associated liver disease. Safety data in children is primarily from open-label studies and clinical registries, with no pediatric-specific safety signals identified beyond those seen in adults. In geriatric patients, no dose adjustment is recommended; the safety profile in patients over 65 years mirrors that of the general adult population.
Paradoxically, UDCA is indicated for patients with hepatic impairment (PBC, PSC), and no dose adjustment is required based on liver function alone. In decompensated cirrhosis (Child-Pugh Class C), the benefit-risk ratio shifts: UDCA should be used with caution, and higher doses (28-30 mg/kg/day) have been associated with increased adverse events in this population per the Mayo Clinic trial data. No dose adjustment is recommended for renal impairment; bile acids are primarily excreted via the biliary route, not renally.
The WHO VigiBase database (the largest global pharmacovigilance repository maintained by the Uppsala Monitoring Centre) contains adverse event reports for UDCA spanning from its first approval to the present. The most commonly reported adverse events in VigiBase align with clinical trial data: gastrointestinal disorders (diarrhea, nausea), with no novel or unexpected safety signals emerging over decades of use.
A 2014 integrated safety analysis of 27 clinical trials (Lindor et al., Hepatology) including 2,054 patients treated with UDCA at doses of 13-15 mg/kg/day for PBC found:
From a procurement and quality perspective, UDCA's well-characterized safety profile reduces several categories of business risk:
This page is a safety reference for pharmaceutical industry professionals and does not constitute medical advice. Prescribing decisions must be made by qualified healthcare providers based on individual patient assessment and current labeling.
Safety data is current as of July 2026. Consult the latest prescribing information, pharmacopoeia monographs, and DrugBank for updates.
Key references: FDA prescribing information (NDA 019593/019594), EMA SmPC (Ursodeoxycholic Acid), Lindor 1994, Lindor 2014, WHO VigiBase, Chappell 2019 (PITCHES).
Page last updated: July 2026
KingWish UDCA is manufactured under GMP with full pharmacovigilance compliance. Request safety documentation.
| Pregnancy Category | Category B (FDA legacy) |
|---|---|
| Most Common AE | Diarrhea (2-9%) |
| Serious AE Rate | 11% (same as placebo) |
| Discontinuation Rate | 3% (same as placebo) |
| Hepatotoxicity | None — hepatoprotective |
| DrugBank Link | DB01586 |